Dogwood Therapeutics (DWTX)
NASDAQ:DWTX
DWTX Stock Chart & Stats
$3.15
-$0.11(-4.15%)
At close: 4:00 PM EST
$3.15
-$0.11(-4.15%)
Day’s Range― - ―
52-Week Range$1.77 - $9.50
Previous CloseN/A
Volume14.38K
Average Volume (3M)1.54M
Market Cap
$66.47M
Enterprise Value-$2.77M
Total Cash (Recent Filing)$6.52M
Total Debt (Recent Filing)$162.60K
Price to Earnings (P/E)―
Beta2.30
Next Earnings
May 07, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding33,401,554
10 Day Avg. Volume77,367
30 Day Avg. Volume1,536,657
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.46
Price to Sales (P/S)0.00
P/FCF Ratio-2.19
Enterprise Value/Market Cap-0.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit160.48
Enterprise Value/Ebitda0.10
Forecast
1Y Price Target
$13.50Price Target Upside328.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.98
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
External Funding And Program ValidationNational Cancer Institute funding for SP16 acts as external validation of the molecule and enables advancement of clinical testing while reducing early-stage financing pressure for that program.
Intellectual Property And Development ReadinessNew patent filings for a synthetic form of Halneuron together with production of clinical batches support extended commercial exclusivity and readiness to move toward a pivotal study if clinical data are positive.
Phase 2b Clinical ReadoutTopline results from the Phase 2b trial of Halneuron for chemotherapy-induced neuropathic pain could provide clear efficacy evidence and support a regulatory pathway and significant market opportunity in an area with no approved therapies.
Bears Say
Clinical, Regulatory And Intellectual Property RiskValuation is exposed to clinical trial outcomes, regulatory decisions, and intellectual property challenges, which could materially reduce the company's prospects if setbacks occur.
Financing RiskLimited company cash resources create the need for additional financing before key development milestones, increasing the risk of dilution or funding shortfalls for investors.
Revenue And Operating LossesAbsence of product revenues and continued net losses indicate ongoing dependence on external capital and heightened execution risk until commercial products generate income.
Dogwood Therapeutics News
DWTX FAQ
What was Dogwood Therapeutics’s price range in the past 12 months?
Dogwood Therapeutics lowest stock price was $1.77 and its highest was $9.50 in the past 12 months.
What is Dogwood Therapeutics’s market cap?
Dogwood Therapeutics’s market cap is $66.47M.
When is Dogwood Therapeutics’s upcoming earnings report date?
Dogwood Therapeutics’s upcoming earnings report date is May 07, 2026 which is in 23 days.
How were Dogwood Therapeutics’s earnings last quarter?
Dogwood Therapeutics released its earnings results on Apr 06, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.86 by $0.6.
Is Dogwood Therapeutics overvalued?
According to Wall Street analysts Dogwood Therapeutics’s price is currently Undervalued.
Does Dogwood Therapeutics pay dividends?
Dogwood Therapeutics does not currently pay dividends.
What is Dogwood Therapeutics’s EPS estimate?
Dogwood Therapeutics’s EPS estimate is -0.19.
How many shares outstanding does Dogwood Therapeutics have?
Dogwood Therapeutics has 33,401,554 shares outstanding.
What happened to Dogwood Therapeutics’s price movement after its last earnings report?
Dogwood Therapeutics reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.86. Following the earnings report the stock price went down -3.318%.
Which hedge fund is a major shareholder of Dogwood Therapeutics?
Currently, no hedge funds are holding shares in DWTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dogwood Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.36%
12-Months-Change
Fundamentals
Return on Equity
-56.64%
Trailing 12-Months
Asset Growth
-10.43%
Trailing 12-Months
Company Description
Dogwood Therapeutics
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
DWTX Stock 12 Month Forecast
Average Price Target
$13.50
▲(328.57% Upside)
Technical Analysis
Marker Therapeutics
―
BioRestorative Therapies
―
Sensei Biotherapeutics
―
Bolt Biotherapeutics
―
Acurx Pharmaceuticals
―
Ownership Overview
74.08% Insiders
0.10% Mutual Funds
<0.01% Other Institutional Investors
25.77% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---